BioNTech comments:
"Very encouraged by the spirit of discussions which really began at the highest levels between Ugur and myself quite a while ago. That spirit has continued and we’re working to sort of finalize that, no update on timing, and we won’t be commenting on it more broadly other than on today’s call." - Jabbour
“Although these discussions have taken more time than perhaps was initially anticipated, the companies remain confident that they will find a mutually acceptable agreement. A license agreement of this potential magnitude and importance takes time and can be complicated, but Matins remains enthusiastic about its relationship and the prospects for a long-term partnership with BioNTech. Both parties continue to engage at the highest levels and with a positive outlook” - IR
"One thing you really have to be in biotech today is that you have to be opportunistic, you have to be flexible and you have to be willing to make the hard decisions. It's very difficult to be a single asset binary decision company, we're not that. We have a benefit of going into the number of different directions. We're doing that with the strength of clinical data. MAT2203 has provided that validation, BioNTech has provided additional validation and some excitement for the future. But we're just getting started in terms of identifying other nucleic acids that we think we can deliver in a way nobody else ever had. So for us it's not a race, this is a marathon. We're smart, we're prudent, we take advantage of the resources we have, we're cash conscious, but we're most focused on building a foundation of what is necessary for building a company that will become a true difference maker across therapeutic categories. Jabbour
“But we have time on our side. I mean, one of the advantages of having already -- have an ongoing relationship with BioNTech is that the science is not stopping. There’s no delay, while the parties figure out what the future looks like, in terms of advancing the platform and the delivery of messenger RNA and other nucleic acids.
And we want the right deal, we want the right deal for our technology, we want the right deal, we obviously have a fiduciary obligation to our shareholders. We think the precedents there. We’re confident that a deal is going to get done and it’s really about putting ourselves in position where we can maximize the opportunity be able to participate in a downstream way and incent BioNTech to create as many product candidates as we can. So that you do have an opportunity to have a meaningful commercial participation as they advance the field of messenger RNA.”
“And at the end of the day, BioNTech came to us, because we have something nobody else has.
And there is obviously a lot of competition in IP, confusion in the lipid nanoparticle space, number one.
And number two, from a technical perspective, our technology facilitates delivery in a way that none of these other technologies could ever imagine..” - Jabbour
0